Indo Borax to buy 64.26% of Kronox for ₹246.12 cr

Deal overview: control change in a listed chemical firm

Promoters of Kronox Lab Sciences have signed a share purchase agreement (SPA) to sell a controlling stake in the listed specialty chemical company to Indo Borax & Chemicals Limited. The transaction covers 2,38,44,000 equity shares, which is about 64.26% of Kronox’s total paid-up equity capital. The SPA was executed on August 20, 2026. The sellers named in the disclosure are Mr. Ketan Vinodchandra Ramani, Mr. Pritesh Vinodchandra Ramani, and Mr. Jogindersingh Gianchand Jaswal.

Indo Borax is acquiring the stake with Zenrock Chemicals Private Limited acting as a person acting in concert (PAC). On completion, Indo Borax along with the PAC will assume control. The disclosures also state that the promoters currently hold 74.21% in Kronox, implying a large part of promoter ownership is being transferred through this SPA.

Who is selling and what they currently own

The disclosed sellers are the existing promoters who, together, hold a combined 74.21% stake in Kronox Lab Sciences. The shareholding data in the material indicates promoter holding has been steady at 74.21% across multiple quarters up to June 2026. That stability makes the August 20, 2026 SPA a clear inflection point for control and governance.

Kronox is described as a manufacturer of high-purity fine, inorganic, phosphate, and metallic chemicals, incorporated in 2008. The company is positioned as a specialty and fine chemicals player, supplying chemicals used as inputs such as raw materials, reagents, processing agents, and excipients across industries. The disclosure also notes the business does not manufacture finished drugs.

Acquirer and PAC: Indo Borax with Zenrock

Indo Borax & Chemicals Limited is the acquirer in the transaction. Zenrock Chemicals Private Limited (ZCPL) is participating as a PAC with Indo Borax. The board of Indo Borax, at its meeting held on Thursday (August 20, 2026), approved execution of the SPA for acquiring the 2.38 crore shares representing 64.26% of Kronox.

The exchange filing also highlights the regulatory threshold impact: following the acquisition, Indo Borax & Chemicals will acquire control and voting rights in excess of 25% of the voting share capital of Kronox Lab Sciences. That triggers obligations under takeover regulations, which is why an open offer has been announced.

Price terms: SPA price and the “effective” price

The base price under the SPA is stated as ₹103.22 per equity share. Separately, a note in the disclosure mentions that when consultancy fees payable by Kronox to the sellers for transition support are included, the effective price rises to ₹105.87 per share. This “effective price” is referenced as being calculated under Regulation 8(7) of the SAST Regulations.

This distinction matters for investors because the disclosed effective price captures value transferred through arrangements linked to the transaction, not only the headline per-share SPA price. The filing explicitly separates the SPA price and the effective price inclusive of consultancy fees, rather than presenting them as the same metric.

Total consideration: ₹246.12 crore for 64.26%

Indo Borax’s disclosure states the aggregate consideration for the acquisition is ₹246 crore. Another disclosure in the provided material states an aggregate consideration of ₹246.12 crore for acquiring 64.26%. The share count and SPA per-share price are also restated: 2.38 crore equity shares at ₹103.22 per share.

While the consideration is clearly disclosed, the market will also track the open-offer size and price as a separate leg of the transaction. Together, the SPA plus the open offer determine how much additional public float could tender at the offer price and what the eventual shareholding could look like after completion.

Open offer: up to 25.79% at ₹157.27 per share

Alongside the SPA, Indo Borax along with ZCPL will make an open offer to public shareholders. The offer is to acquire up to 95.7 lakh equity shares, which is about 25.79% of Kronox’s voting share capital. The offer price for public shareholders is set at ₹157.27 per equity share, and is stated to be determined in accordance with SAST regulations.

The size of the open offer mirrors the disclosed investor (non-promoter) holding figure of 25.79% shown in the shareholding snapshot, providing a clear reference point for how much of the public shareholding is being targeted under the offer.

Stock reaction: upper circuit move after approval

Kronox Lab Sciences shares surged 20% to hit the upper circuit limit in Thursday’s trading session after Indo Borax & Chemicals approved the acquisition of the 64.26% stake. Separate market data in the provided material shows Kronox trading on BSE at ₹157.90 (+3.47%) at 02:37 PM on the same day, and another cited price point is ₹154.49 as the “current share price.”

The market move came in the context of a control transaction with a disclosed open offer price of ₹157.27 per share. Investors also had to process the difference between the SPA price (₹103.22), the effective price including transition consultancy fees (₹105.87), and the open-offer price (₹157.27).

Key deal numbers at a glance

Company context: size, business profile, and financial snapshot

Kronox Lab Sciences is described as a specialty and fine chemicals manufacturer with a product range of about 185 to 188 high-purity fine, inorganic, and specialty chemicals. The material also provides a revenue figure: FY26 revenue of ₹101.2 crore. Market capitalisation references in the provided data range around ₹526 crore to about ₹560 to ₹575 crore, reflecting different snapshots.

The shareholding data shows promoter holding of 74.21% and investors holding of 25.79% in recent quarters up to June 2026. The same dataset notes FII/FPI holding of about 0.04% and DII holding of about 2.07% as of June 2026. These ownership details help explain why a single SPA can result in an immediate change of control and a mandatory open offer.

Market impact: what investors should track now

The disclosed structure creates three important price anchors for the market: the SPA price (₹103.22), the effective price including transition consultancy fees (₹105.87), and the open offer price (₹157.27). With Kronox hitting an upper circuit on the day of the announcement, the near-term price action is likely to remain sensitive to formal open-offer timelines and shareholder response.

Operationally, the transition support arrangement is explicitly mentioned, indicating that sellers may continue to provide consultancy to support handover. For investors, the key next steps typically centre on completion conditions for the SPA, open-offer process milestones under SAST, and eventual post-transaction shareholding and board control once the acquisition closes.

Why the deal matters: control, compliance, and valuation signals

A 64.26% stake purchase is a decisive change in control for a listed company and is also large enough to reshape governance, voting outcomes, and strategic direction. The disclosure that Indo Borax will have voting rights in excess of 25% highlights the regulatory trigger points that bring SAST rules into play. The open offer for up to 25.79% at ₹157.27 is especially relevant because it provides a publicly disclosed reference price for minority shareholders.

At the same time, the gap between the SPA price and the open-offer price, and the separate disclosure of an effective price under Regulation 8(7), are key elements for investors reading the filings closely. These figures can influence how the market interprets the economics of the control transfer and the terms offered to public shareholders.

Conclusion

Indo Borax & Chemicals has approved and entered into an SPA to acquire 64.26% of Kronox Lab Sciences for an aggregate consideration disclosed at ₹246 crore to ₹246.12 crore, with Zenrock Chemicals acting as a PAC. The transaction includes an open offer for up to 25.79% of the voting share capital at ₹157.27 per share. The next market focus will be on completion of the SPA and the open-offer process as per SAST timelines and disclosures.